Oppenheimer reiterates Outperform on UroGen Pharma stock at $60
Covered in this story
What has happened since
- Urogen Pharma LTD is down 22.4% since this was published, 17 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Oppenheimer’s $60 target on $URGN is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
Oppenheimer’s track record →Analyst targets on Urogen Pharma LTD
- H.C. Wainwright: at $35 · target $75 by Oct 2027 · Buy via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $URGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Urogen Pharma LTD →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.